Journal of Clinical Oncology
Articles in this Issue
Effect of CF33-hNIS oncolytic virus on M2 macrophages and tumor microenvironment in gastric cancer.
432 Background: Gastric cancer peritoneal metastasis (GCPM) has limited therapeutic options and dismal prognosis. Oncolyti...
Exploration of HER2 expression in advanced hepatocellular carcinoma using tumor biopsy samples.
595 Background: HER2 is an established therapeutic target in breast, gastric, and lung cancers, and trastuzumab deruxtecan...
Early outcomes of the PLATO ACT5 randomised trial: Personalizing anal cancer radiotherapy dose.
1 Background: The optimal dose of radiotherapy (RT) in advanced anal squamous cell carcinoma (ASCC) is uncertain. Cure rat...
Comparison of surgical procedures and short- and mid-term outcomes for transverse colon cancer: A retrospective study from a single center.
39 Background: For transverse colon cancers located in the right to mid portion, right hemicolectomy (RHC) and transverse...
Evaluating robotic vs. laparoscopic liver resection for BCLC stage 0–I hepatocellular carcinoma: A meta-analysis of propensity score-matched studies on perioperative outcomes.
534 Background: Liver resection is a key treatment for hepatocellular carcinoma (HCC). Robotic liver resection (RLR) offer...
Efficacy and safety of ASP3082 monotherapy or in combination with mFOLFIRINOX in patients (pts) with pancreatic ductal adenocarcinoma (PDAC).
704 Background: KRAS G12D mutations occur in ~40% of pts with PDAC and are linked to poor prognosis. ASP3082, a first-in-c...
Comparative analysis of potentially actionable genomic alterations in early-onset versus later-onset gastrointestinal cancers.
846 Background: There is an alarming rise in early-onset (EO) gastrointestinal (GI) cancers, which may have distinct genom...
Pancreatic metastases from small cell lung cancer: Systematic review of clinical presentation, diagnosis, and outcomes.
656 Background: Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with frequent metastasis to the l...
Investigating clinical and molecular characteristics of patients with PIK3CA mutation with and without KRAS mutations in colorectal cancer.
201 Background: PIK3CA mutations are some of the most common somatic mutations in colorectal cancer (CRC) and can be seen...
Comprehensive whole-genome analysis of colorectal cancer (CONDUCTOR study): Integrating RAS/BRAF, MSI status, and intron–exon alterations.
181 Background: Molecular profiling of colorectal cancer (CRC) has traditionally centered on RAS, BRAF, and microsatellite...
A single institutional analysis of missed opportunities in Lynch syndrome diagnosis.
95 Background: The National Comprehensive Cancer Network (NCCN) recommended germline testing for all patients with early o...
Phase 2 study of cabozantinib (Cabo) combined with ipilimumab (Ipi)/nivolumab (Nivo) and transarterial chemoembolization (TACE) in patients with liver limited unresectable hepatocellular carcinoma (uHCC).
543 Background: The purpose of this study is to test the safety and efficacy of a multimodality approach in liver limited...
Predictors of two-year survival in patients receiving chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC): A single-center retrospective cohort study.
666 Background: Median survival in patients with mPDAC is typically between 6 and 11 months, and survival of more than two...
Progression-free survival with the ICE regimen in refractory RAS/BRAF wild-type and MSS mCRC patients.
131 Background: For patients with refractory metastatic colorectal cancer, current therapeutic options are with limited ef...
A phase 2 randomized study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with standard of care (SOC) in patients with metastatic colorectal cancer.
TPS255 Background: c-Met protein is often expressed in several solid tumors, including metastatic colorectal cancer (mCRC)...
Baseline biomarker analysis and clinical outcomes of the PD-1/TGFβR2 bispecific antibody INCA33890 in patients with non-MSI-H metastatic colorectal cancer (mCRC).
186 Background: INCA33890 is an anti–PD-1/TGFβR2 bispecific antibody designed to antagonize TGFβR2/PD-1 signaling in immun...
Randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for metastatic or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).
TPS461 Background: Nivolumab plus ipilimumab (NIVO+IPI) is one of the standard first-line treatments for advanced or recur...
Machine learning-based detection of multiple cancers using 5-hydroxymethylcytosine at cancer mutation hotspot as marker.
806 Background: 5-hydroxymethylcytosine (5hmC) is an important DNA epigenetic modification that has been linked to gene re...
Real-world outcomes of hepatic arterial infusion pump therapy.
69 Background: Hepatic artery infusion (HAI) with floxuridine (FUDR) is a liver directed therapy for (pts) with unresectab...
Feasibility of consensus molecular subtype classification of colorectal cancer using preoperative biopsy specimens: A prospective pilot study.
180 Background: Consensus molecular subtype (CMS) classification stratifies colorectal cancer (CRC) into four groups based...
Long-term efficacy of celiac plexus radiosurgery for pancreatic cancer pain: An international phase II trial.
714 Background: Celiac plexus radiosurgery demonstrates impressive short-term pain control (3-6 weeks) in pancreatic cance...
Small cell carcinoma of the esophagus: A SEER-based analysis of stage-stratified radiotherapy outcomes and histologic comparisons.
362 Background: Primary small cell carcinoma of the esophagus (SCEC) is a rare and aggressive malignancy, representing <...
Beyond regimen selection: Systemic therapy completion and host determinants as predictors in localized upper gastrointestinal adenocarcinoma.
315 Background: Perioperative systemic therapy is standard in localized upper gastrointestinal (UGI) cancers, yet real-wor...
Bevacizumab-atezolizumab (B-A), durvalumab-tremelimumab (D-T) and lenvatinib (L) in advanced hepatocellular carcinoma patient therapy: An efficacy comparison study based on real-world evidence.
516 Background: B+A, D+T and L are recognized as standard first-line therapy in aHCC patients, but there are no direct com...
Socioeconomic barriers and missed opportunities for early diagnosis in young-onset biliary tract cancer in Appalachian region.
533 Background: Biliary tract cancers (BTCs) are aggressive malignancies often diagnosed at advanced stages, with majority...